19 October 2023
In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone. The study concludes that primary resistance to PD-1 blockade therapy can be reversed in some patients with the combination of CTLA-4 and PD-1 blockade.
19 October 2023
The objective of this recent study was to compare outcomes of wide (10 mm margins) versus narrow (5 mm margins) excisions in patients with radial growth phase T1 melanoma (invasive melanomas with Breslow thickness ≤1 mm) on head-and-neck including face. Authors conclude that narrower excision margins are not associated with worse overall survival or increased local recurrence compared to wider margins, and may be safely applied to such lesions, although caution may be required in the presence of lentigo maligna melanoma.
19 October 2023
Electrodesiccation and curettage (EDC) is a common, minimally invasive treatment of cutaneous squamous cell carcinoma in situ (SCCIS). According to this recent study, EDC allows for a high 5-year cure rate across a broad range of anatomic sites. However, overall cure rate should be individualized by anatomic location when counseling patients.
19 October 2023
According to this recent cohort study of 318 patients with advanced or metastatic melanoma who received adjuvant anti–PD-1, chronic immune-related adverse events were common, affected diverse organ systems, and often persisted with long-term follow-up requiring steroids and additional management. Findings highlight the likelihood of persistent toxic effects when considering adjuvant therapies and need for long-term monitoring and management.
17 October 2023
According to this recent study, community pharmacies and pharmacists have the potential to be change agents in skin cancer prevention by providing education on sun protection or detection and by promoting sun-safety behaviors.
17 October 2023
According to the PIVOT IO 001 study, Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) combination therapy provided no additional clinical benefit compared with NIVO monotherapy in patients with previously untreated unresectable or metastatic melanoma. A higher incidence of treatment-related adverse events with a lack of added efficacy was noted with BEMPEG plus NIVO versus NIVO alone.
17 October 2023
According to this recent study, better patient education regarding the reduction of skin cancers with oral nicotinamide will need to be implemented to change patients’ perceptions of the value of nicotinamide.
17 October 2023
Findings of this recent study reveal the genetic features of patients with mucosal melanoma, mainly across six anatomic sites, offering a potential avenue for targeted therapies.
17 October 2023
According to this recent study, genomic risk provision targeted to high-traditional melanoma risk individuals is likely a cost-effective strategy for reducing sunburns and will likely prevent future melanomas and keratinocyte carcinomas.
4 September 2023
This study aims at clarifying the existence of the clinically invisible, early stages of actinic keratosis (AKs) on chronically UV-exposed skin without showing clinically evident features of AK.
